Genmab — September 2015
-
n this case, one should bear in mind that 50% of the patients in the DARA SIRUS study had also received Carfilzomib, underpinning the impressive response and survival data further. The FDA’sapproval data for DARA, based on the SIRIUS data, the Breakthrough Therapy Designation and the Priority Review is 9March, but we do not see it as unlikely with an approval already in 2015
-
Link til interview (3:20min inde): https://www.youtube.com/watch?v=7Tkp88aLW1M&noredirect=1
-
fedt fedt. Og slutter med "so there will be more headline news on dara? Yes definetly"
-
Jeg lagde linket i debatten lørdag nat. Så er det nemmere at finde frem til: http://www.proinvestor.com/debat/73220
-
Skal vi så lige tage en lukkeauktion som i fredags?
-
Jeps..Men trods alt en godkendt dag.
-
Det regnestykke kan vi godt lide JKY.
-
Hvad dælen sker der lige i US!!!?
-
-
forklarer det hvorfor biotekindexet er nede 4,5%?
-
Ok..Det så jeg så ikke.
-
Det er Hillary, den onde heks, der er efter os - http://www.cnbc.com/2015/09/21/biotech-falls-on-clinton-price-gouging-comments.html
-
Vi nærmer os et fald på 5% på en time - det er sgu da seriøse sager!
-
Kan det bare ikke være nogle tungvægtere som trækker det ned?
-
Det er helt klart en overreaktion.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind